NCT03621839 · RECRUITING
New CSF Biomarkers for Alzheimer's Disease
This study is collecting leftover cerebrospinal fluid (CSF) — the fluid drawn during routine lumbar punctures for dementia diagnosis — to test new biological markers that might one day help diagnose or track Alzheimer's disease. It is not testing a treatment. It is an observational biobank study, meaning researchers are gathering samples to validate future tools, not to prove a drug works.
You may qualify if
- Lumbar punction collected in usual practice in the context of dementia diagnosis
You're excluded if
- Absence of consent
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2024-03-06